Bill Text: HI HB2567 | 2020 | Regular Session | Introduced

---

Bill Title: Relating To Psilocybin.

Spectrum: Partisan Bill (Democrat 7-0)

Status: (Introduced - Dead) 2020-01-30 - The committee(s) on HLT recommend(s) that the measure be deferred. [HB2567 Detail]

Download: Hawaii-2020-HB2567-Introduced.html

---

HOUSE OF REPRESENTATIVES	H.B. NO.	2567
THIRTIETH LEGISLATURE, 2020
STATE OF HAWAII

A BILL FOR AN ACT

 

 

RELATING TO PSILOCYBIN.

 

 

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

 

     SECTION 1.  The legislature finds that studies conducted by nationally- and internationally-recognized medical institutions indicate that psilocybin has shown efficacy, tolerability, and safety in the treatment of a variety of mental health conditions, including addiction, depression, anxiety disorders, and end-of-life psychological distress.  Additionally, the United States Food and Drug Administration has determined that preliminary clinical evidence indicates that psilocybin may demonstrate substantial improvement over available therapies for treatment-resistant depression and has granted a "breakthrough therapy" designation for a treatment that uses psilocybin as a therapy for treatment-resistant depression.

     The purpose of this Act is to establish a medicinal psilocybin working group that is tasked with developing a long-term strategic plan to ensure that psilocybin services will become and remain safe, accessible, and affordable therapeutic options for all state residents twenty-one years of age and older for whom psilocybin may be appropriate.

     SECTION 2.  (a)  There is established a medicinal psilocybin working group, to be placed in the department of health for administrative purposes.

     (b)  The medicinal psilocybin working group shall examine:

     (1)  Federal, state, and local laws, regulations, and procedures, regarding the medicinal use of psilocybin;

     (2)  Available medical, psychological, and scientific studies, research, and other information relating to the safety and efficacy of psilocybin in treating mental health conditions; and

     (3)  Requirements, specifications, and guidelines for a medical professional to prescribe and provide psilocybin.

     (c)  The medicinal psilocybin working group shall develop a long-term strategic plan to ensure the availability of medicinal psilocybin or psilocybin-based products that are safe, accessible, and affordable for those twenty-one years of age or older.

     (d)  The medicinal psilocybin working group shall consist of the following members or their designees:

     (1)  The director of health, who shall serve as chair of the working group;

     (2)  The attorney general;

     (3)  The dean of the John A. Burns School of Medicine;

     (4)  The chairs of the senate and house subject matter committees primarily responsible for reviewing legislation relating to health;

     (5)  The chairs of the senate and house subject matter committees primarily responsible for reviewing legislation relating to the judiciary;

     (6)  A physician duly licensed under chapter 453, Hawaii Revised Statutes, or advanced practice registered nurse with the authority to prescribe psychotropic medication under chapter 457, Hawaii Revised Statutes, to be invited by the chair of the working group;

     (7)  A psychiatrist duly licensed under chapter 453, Hawaii Revised Statutes, to be invited by the chair of the working group; and

     (8)  Any other members with relevant experience relating to the work of the working group.

     (e)  The medicinal psilocybin working group shall submit a preliminary report of its findings and recommendations to the legislature no later than twenty days prior to the convening of the regular session of 2021, and a final report of its findings and recommendation, including any proposed legislation, to the legislature no later than twenty days prior to the convening of the regular session of 2022.

     (f)  The medicinal psilocybin working group shall dissolve on July 1, 2022.

     SECTION 3.  This Act shall take effect upon its approval.

 

INTRODUCED BY:	_____________________________

 

 

Report Title:

Psilocybin; Working Group; Department of Health

 

Description:

Establishes temporary Medicinal Psilocybin Working Group.  Requires reports to the Legislature.

 

 

 

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.